Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of British Columbia

$33,000.00

Mechanistic structure-function studies of the type II citrate synthase of gram-negative bacteria

FY 2015-16

Summary
Gram-negative bacteria are involved in a wide range of different diseases in plants, animals and humans, with severe economic and health consequences. These range from soft rot in agricultural crops, to contamination of processed foods, and include many of the most dangerous human pathogens (E. coli, N. gonorrhoea, P. aeruginosa, S. typhi, V. cholerae, etc.). Also notable is the fact that Gram-negative bacteria have a unique form of the energy producing enzyme, citrate synthase, designated Type II, whereas most other organisms, including humans, express the Type I dimeric version of this enzyme. Type II citrate synthases form hexamers that are metabolically regulated through strong allosteric inhibition by NADH. As such, these enzymes exhibit a conformational equilibrium between the T (inactive, binding NADH) and R (active, binding substrates) states. In the research program outlined in this application, a strongly synergistic series of mechanistic and inhibitor discovery experiments are proposed. The goal is to not only attain a comprehensive understanding of the unique allosteric function of Type II citrate synthases, but also to explore the possibility of using this knowledge to develop novel anti-bacterials that lock these enzymes into the T inactive state and thereby achieve pathogenic clearance by choking off the energy supply of Gram-negative bacteria. Remote allosteric control as a paradigm for anti-bacterial control is an entirely new approach to the eradication of pathogens, a process that has traditionally depended on direct active site inhibition. We have recently demonstrated the validity of the allosteric lock down approach in a small pilot screening study that identified three new potential anti-bacterials. To build on this success we propose the following mechanistic studies of the Type II citrate synthases: structurally characterizing the R-state; mapping the route of allosteric signal transmission; and, characterizing the nature of allosterically directed active site unfolding. To further the goals of anti-bacterial inhibitor discovery, we further propose to: expand our successful pilot screening program; functionally test identified potential inhibitors; and, structurally characterize the modes of allosteric lock inhibition observed.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
183640-2010
Name nom
Brayer, Gary
Department département
Biochemistry and Molecular Biology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2010
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
5
Nb partie
5
Application title
Mechanistic structure-function studies of the type II citrate synthase of gram-negative bacteria
Keyword
NSERC
Application summary
Gram-negative bacteria are involved in a wide range of different diseases in plants, animals and humans, with severe economic and health consequences. These range from soft rot in agricultural crops, to contamination of processed foods, and include many of the most dangerous human pathogens (E. coli, N. gonorrhoea, P. aeruginosa, S. typhi, V. cholerae, etc.). Also notable is the fact that Gram-negative bacteria have a unique form of the energy producing enzyme, citrate synthase, designated Type II, whereas most other organisms, including humans, express the Type I dimeric version of this enzyme. Type II citrate synthases form hexamers that are metabolically regulated through strong allosteric inhibition by NADH. As such, these enzymes exhibit a conformational equilibrium between the T (inactive, binding NADH) and R (active, binding substrates) states. In the research program outlined in this application, a strongly synergistic series of mechanistic and inhibitor discovery experiments are proposed. The goal is to not only attain a comprehensive understanding of the unique allosteric function of Type II citrate synthases, but also to explore the possibility of using this knowledge to develop novel anti-bacterials that lock these enzymes into the T inactive state and thereby achieve pathogenic clearance by choking off the energy supply of Gram-negative bacteria. Remote allosteric control as a paradigm for anti-bacterial control is an entirely new approach to the eradication of pathogens, a process that has traditionally depended on direct active site inhibition. We have recently demonstrated the validity of the allosteric lock down approach in a small pilot screening study that identified three new potential anti-bacterials. To build on this success we propose the following mechanistic studies of the Type II citrate synthases: structurally characterizing the R-state; mapping the route of allosteric signal transmission; and, characterizing the nature of allosterically directed active site unfolding. To further the goals of anti-bacterial inhibitor discovery, we further propose to: expand our successful pilot screening program; functionally test identified potential inhibitors; and, structurally characterize the modes of allosteric lock inhibition observed.